{
  "docId": "019de076-8fd6-709e-8689-4f849e880c13",
  "docSlug": "045f5237a1062f1479093c113a295dbd",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 29 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 29,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8fd6-709e-8689-4f849e880c13/16",
  "deckHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13",
  "deckJsonHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13.json",
  "deckAnchorHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "image",
      "text": "Brain diagram showing pathways for wakefulness, dopamine, serotonin, and norepinephrine.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59014059-9c07-4f35-a03e-ef41bcdac29a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "In narcolepsy, low orexin levels lead to inconsistent neurotransmitter release, resulting in excessive sleepiness and poor regulation of REM sleep. Narcolepsy (types 1 and 2) affects ~200,000 people in U.S. and 3M people globally. 70% of people with narcolepsy have narcolepsy type 1 (NT1), distinguished by: Cataplexy, a sudden muscle weakness triggered by strong emotions; Low or no orexin in the brain. People with narcolepsy type 2 experience excessive daytime sleepiness but not cataplexy and generally have normal levels of orexin. Genetic and pharmacologic evidence suggests that orexin receptor agonists, especially OX2R agonists, may be useful for mechanistic therapy of narcolepsy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc4f733d-0289-4e61-ae9d-cc86b0a31cf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1 Global Narcolepsy Drugs Market, Forecast 2019-2025. Allied Market Research. 2 Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep. 2015;7:159-169. 3 Nagahara T. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J. Med. Chem. 2015;58:7931-7937. OX2R: orexin 2 receptor. Figure from: Scammell, T E, and Saper, C B. Nature medicine. 2007;13:126-8",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f595d1bc-e00c-41ab-9cc8-bc4bf2d2ccf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "010d69aa-c136-4f07-b5ff-07ebd812510c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "b1f8cbeb-ac7e-4bf4-a4e5-3a674283144e",
      "evidence": "The slide clearly defines a problem statement, including the key issues and statistics, which is a key element of the problem statement canvas.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 16,
      "beatId": "c1b0dfb9-8e00-407e-80d0-73d097a8aa29",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Complication",
      "beatSlug": "complication",
      "evidence": "The deck presents a problem statement on orexin dysfunction.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "58d89332-74ab-4a79-b132-80fa9e87fcdc",
      "evidence": "The deck presents a problem statement on orexin dysfunction and Alkermes' solution.",
      "position": 0,
      "objective": "What if Alkermes doesn't address orexin dysfunction?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}